NCT05432804: Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 97 planned
- Started
- 20 Mar 2023
- Primary completion
- 30 Jun 2027
- Arms
- Group II (temozolomide, selinexor)
- Results
- None posted
- 27 Jun 2022: Trial registered
- 20 Mar 2023: Trial started